Table 1.
Patient, Disease, and Treatment Characteristics
| Characteristic | HIV+ NHL1 (Case) N=29 |
HIV-NHL1 (Control) N=29 |
p-value2 |
|---|---|---|---|
| Patient Gender | |||
| Female | 2 (7) | 2 (7) | 0.99 |
| Male | 27 (93) | 27 (93) | |
| Age at ASCT (Years) | 42 (11–68) | 48 (21–65) | 0.06 |
| Histology | |||
| Diffuse Large B-Cell | 14 (48) | 22 (76) | --- |
| Mediastinal Large B-Cell | 0 (0) | 1 (3) | |
| Marginal Zone B-Cell | 0 (0) | 1 (3) | |
| Immunoblastic Large B-cell | 2 (7) | 0 (0) | |
| Burkitt Lymphoma | 11 (38) | 0 (0) | |
| Follicular Lymphoma | 0 (0) | 4 (14) | |
| Anaplastic Large Cell | 2 (7) | 1 (3) | |
| Stage at Diagnosis | |||
| I | 1 (3) | 4 (14) | 0.41 |
| II | 1 (3) | 2 (7) | |
| III | 8 (28) | 6 (21) | |
| IV | 19 (66) | 17 (58) | |
| Bone Marrow Involvement at Diagnosis |
|||
| Yes | 8 (28) | 9 (31) | 0.74 (Yes vs. |
| No | 18 (62) | 18 (62) | No) |
| Unknown, Test Not Done | 3 (10) | 2 (7) | |
| Extranodal Disease at Diagnosis | |||
| Yes | 20 (69) | 18 (62) | 0.56 (Yes vs. |
| No | 8 (28) | 11 (38) | No) |
| Test Not Done | 1 (3) | 0 (0) | |
| Time from Diagnosis to ASCT (Months) |
11.7 (0.2– 115.3) |
12.6 (5.8– 205.6) |
0.25 |
| Number of Prior Regimens | 2 (1–4) | 2 (1–4) | 0.33 |
| Chemo Sensitivity | |||
| Yes | 23 (79) | 27 (93) | 0.10 |
| No | 6 (21) | 2 (7) | |
| Disease Status at ASCT | |||
| CR/PR | 20 (69) | 20 (69) | 0.61 |
| Relapse | 7 (24) | 6 (21) | |
| IF | 2 (7) | 3 (10) | |
| ASCT Conditioning Regimen | |||
| FTBI/VP16/CY | 4 (14) | 4 (14) | 0.32 |
| BCNU/VP16/CY | 25 (86) | 22 (76) | |
| BEAM | 0 (0) | 3 (10) | |
1
Reported as number of patients (percent) or median (range)
2
McNemar’s X2 test applied for categorical data; Wilcoxon Rank Sum test applied for continuous data